Catalyst Awardee

Project Description

Development and dissemination of an artificial intelligence-assisted assessment system for cardiotoxicity of immunotherapy in elderly oncology patients

Leilei Cheng, MD, PhD | Zhongshan Hospital, Fudan University; Yan Wang, MD, Hao Lu, MD, Huiyong Chen, MD
Competition Sponsor:
 Chinese Academy of Medical Sciences
Awardee Year: 2023

China’s elderly population is increasing rapidly, and the incidence of cancer is much higher than that of young people. It is expected that the population over 69 years old will exceed 400 million in 2035, accounting for more than 30% of the population, posing significant medical challenges. Immune checkpoint inhibitors (ICIs) have achieved great success in cancer treatment, but ICI-related myocarditis is a serious side effect, with an incidence rate of 1.14% and a mortality rate as high as 66%, which is particularly dangerous. Additionally, elderly patients may not only “have a tumor” but also “have it in their heart.” In order to meet the needs of elderly Chinese oncology patients, the project has established a multidisciplinary joint clinic, and the “ICIs Myocarditis Online Assessment Applet,” developed with AI technology, has been trialed in many hospitals to aid in early identification, accurate staging, and standardized treatment. By promoting the multidisciplinary joint clinic mechanism through WeChat, the project has enhanced its capability to manage the entire process of ICI-related myocarditis and has ensured that elderly cancer patients can safely reap the survival benefits of immunotherapy.”

Sign up for updates